Eton Pharmaceuticals, Inc. ETON Uridine Triacetate — Payments To Acquire Marketing Rights

Similar metrics at other companies

XOMAPayment To Acquire Intellectual Property Net

-$5.04M—

DYNPayments To Acquire Other Productive Assets

$4.7M—

HALOPayment To Acquire In Process Research And Development, Net Of Cash Acquired

$71.94M—

KEE

KEELPayments To Acquisitions Of Assets

$1.41M—

CWENPayment to Acquire Assets, Net of Cash Acquired

$0-100%

ADTNPayments to Acquire Intangible Assets

$8.44M-25.3%

Other financials

Income statement

See full

Revenue$24.3M+40.4%

Gross profit$14.7M+49.4%

Operating income$2.4M+614%

Net income$1.6M+199%

EPS (diluted)$0.05+183%

Balance sheet

See full

Cash & equivalents$19.7M+12.9%

Total debt$31.3M+3.7%

Total equity$30.6M+25.2%

Total assets$97.7M+16.3%

Cash flow

See full

Operating cash flow$7.4M+254%

CapEx$75.0K—

Free cash flow$7.3M+251%

Valuation

See full

Market cap$953.8M+162%

Enterprise value$965.4M+156%

P/S11×+3.4×

Profitability

See full

Gross margin54.8%-3.7pp

Operating margin-15.1%—

Net margin-9.5%-2.7pp

FCF margin17.1%—

Returns & leverage

See full

Return on equity-34.2%+0.9pp

Debt / equity1×-0.2×

Current ratio1.2×-0.8×

Where this comes from

Reported directly by Eton Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept eton:PaymentsToAcquireMarketingRights.

The official record: Eton Pharmaceuticals, Inc.’s 10-K, filed March 19, 2026, on SEC EDGAR. View the filing →

Ask your AI about Eton Pharmaceuticals, Inc.'s uridine triacetate — payments to acquire marketing rights.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Eton Pharmaceuticals, Inc.'s uridine triacetate — payments to acquire marketing rights?: Eton Pharmaceuticals, Inc. (ETON) reported uridine triacetate — payments to acquire marketing rights of $1M in Q1 2026.
What does uridine triacetate — payments to acquire marketing rights mean?: This metric represents the total cash outflows or contractual obligations incurred to secure the exclusive rights to market and distribute a specific pharmaceutical product. It reflects the upfront or milestone-based capital investment required to build the company's product portfolio. Monitoring these payments helps investors assess the cost of business development and the company's strategy for expanding its rare disease pipeline.